Clinical trialsCompany release

FDA allows Alpha Tau to double REGAIN glioblastoma trial to 20 patients

Alpha Tau Medical Ltd. (DRTS) · Thu 19 Nov 2026

Alpha Tau Medical says the US regulator approved an IDE supplement after interim data on Alpha DaRT in recurrent glioblastoma, as the firm reported Q3 2026 results.

Alpha Tau Medical reported third-quarter 2026 results on 19 November, alongside a corporate update on its Alpha DaRT alpha-radiation therapy. The most significant regulatory item was an FDA decision in October 2026 to approve an investigational device exemption (IDE) supplement for the REGAIN trial in recurrent glioblastoma.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Alpha Tau Medical Ltd. ↗

Article written by VigiEye from the official source (Alpha Tau Medical Ltd.). Claims are the company's own. AI-assisted; check the source before acting.